CARA - Cara Therapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
41,867
41,867
23,028
135,082
19,886
Cost of revenue
7,266
7,266
-
-
-
Gross profit
34,601
34,601
-
-
-
Operating expenses
Research development
91,879
91,879
82,701
107,851
113,820
Selling general and administrative
30,129
30,257
29,410
21,749
17,745
Total operating expenses
122,136
122,136
112,111
129,697
131,565
Operating income or loss
-87,535
-87,535
-89,083
5,385
-111,679
Total other income/expenses net
2,061
2,061
642
2,334
4,490
Income before tax
-85,474
-85,474
-88,441
7,719
-107,189
Income tax expense
0
0
0
-691
-816
Income from continuing operations
-85,474
-85,474
-88,441
8,410
-106,373
Net income
-85,474
-85,474
-88,441
8,410
-106,373
Net income available to common shareholders
-85,474
-85,474
-88,441
8,410
-106,373
Basic EPS
-
-1.59
-1.74
0.18
-2.49
Diluted EPS
-
-1.59
-1.74
0.18
-2.49
Basic average shares
-
53,654
50,719
47,413
42,669
Diluted average shares
-
53,654
50,719
47,915
42,669
EBITDA
-
-87,535
-89,083
5,594
-111,679